Data Readout

Lantern's LP-300 posts 8.3-month PFS signal in 16 EGFR L858R patients

HARMONIC's randomized OS/PFS readout is still pending in H2 2026, but Lantern has already disclosed a small, non-randomized subgroup result that will need to hold up as enrollment matures.

By AppliedXLJuly 13, 2026Trial NCT05456256

Executive Summary

Lantern Pharma has already released a preliminary clinical signal from its randomized HARMONIC trial, ahead of the fuller data update it has guided for later this year.
The result comes from a narrow genomically defined subgroup, not the trial's full randomized comparison against chemotherapy alone, and multiple statistical comparisons were reported within that small group.
The trial's primary completion date has moved twice since the study began, now landing a year past its original 2024 target, while enrollment has held steady at its original target.
HARMONIC tests whether adding LP-300 to standard carboplatin and pemetrexed improves survival for never-smokers with lung adenocarcinoma carrying targetable genomic alterations, a population defined by exposure history and mutation status rather than a crowded competitive mechanism.

The catalyst

Lantern Pharma said it expects additional clinical data from the Phase 2 HARMONIC trial of LP-300 in the second half of 2026, with the guided window running from July 1 through December 31. That guidance followed an earlier, broader 2026 window the company had set in November 2025, tightening the expected disclosure to the back half of the year. Separately, and ahead of that broader update, Lantern has already reported a preliminary result from the trial: an 8.3-month median progression-free survival in patients with EGFR Exon 21 L858R mutations, drawn from a data cutoff in April 2026. Lantern

Probability of Success

Endpoint Met40%

Completes33%

Clinical Significance20%

Regulatory91%

The design

HARMONIC (NCT05456256) is a randomized, industry-sponsored Phase 2 trial testing LP-300 added to carboplatin and pemetrexed against that chemotherapy doublet alone, in never-smokers with advanced lung adenocarcinoma carrying actionable genomic alterations such as EGFR, ALK, MET exon 14 skipping, or NTRK fusions who have progressed on prior tyrosine kinase inhibitor therapy. The trial targets 90 patients across the United States, Japan, and Taiwan, with two co-primary endpoints, overall survival and progression-free survival, and four secondary endpoints including objective response rate and clinical benefit rate. The disclosed 8.3-month PFS figure and its accompanying hazard ratios of 0.36 (p=0.028) and 0.23 (p=0.036) come from a 16-patient L858R subgroup, not the trial's full randomized comparison, and the sponsor described safety as showing no new or clinically meaningful toxicity added by LP-300. NCT05456256+1

Timing and stability

The trial's primary completion date has moved twice on the public registry: from November 2024 to December 2025 in October 2024, then from December 2025 to December 2026 in May 2026. Enrollment has stayed flat at its original target of 90 patients, a routine hold rather than a cut. The trial expanded into Japan and Taiwan in April 2024 under a regulatory approval to broaden enrollment geography, and Lantern reported a successful Type C meeting with the FDA on the trial in the first quarter of 2026. A Type C meeting is a scheduled FDA discussion on development strategy, not a decision on the drug itself. NCT05456256+1

The competitive frame

No trial in the competitive landscape shares LP-300's target or mechanism class as a validated comparator; the closest analogs are same-modality small-molecule programs in lung adenocarcinoma built around different targets, including EGFR inhibitors such as icotinib, gefitinib, and furmonertinib, and non-EGFR agents such as nintedanib and rigosertib. None of these directly test LP-300's mechanism, and the trial itself is not designed as a registrational study. In a field without a validated disease-modifying comparator for LP-300's specific mechanism, the informative bar for the full randomized readout is whether the survival and progression-free survival benefit implied by the small subgroup extends across the trial's broader genomically defined population and holds up against the chemotherapy control arm. NCT05456256

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.